Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, the Americas, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery. Its hum… Read more
Avecho Biotechnology Limited (AVEFF) - Total Assets
Latest total assets as of June 2025: $7.19 Million USD
Based on the latest financial reports, Avecho Biotechnology Limited (AVEFF) holds total assets worth $7.19 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Avecho Biotechnology Limited - Total Assets Trend (1993–2024)
This chart illustrates how Avecho Biotechnology Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Avecho Biotechnology Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
Avecho Biotechnology Limited's total assets of $7.19 Million consist of 96.3% current assets and 3.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 47.5% |
| Accounts Receivable | $2.25 Million | 45.0% |
| Inventory | $137.46K | 2.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1993–2024)
This chart illustrates how Avecho Biotechnology Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Avecho Biotechnology Limited's current assets represent 96.3% of total assets in 2024, a decrease from 100.0% in 1993.
- Cash Position: Cash and equivalents constituted 47.5% of total assets in 2024, up from 1.2% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1993.
- Asset Diversification: The largest asset category is accounts receivable at 45.0% of total assets.
Avecho Biotechnology Limited Competitors by Total Assets
Key competitors of Avecho Biotechnology Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Avecho Biotechnology Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Avecho Biotechnology Limited generates 0.26x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Avecho Biotechnology Limited is currently not profitable relative to its asset base.
Avecho Biotechnology Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.62 | 3.54 | 7.51 |
| Quick Ratio | 4.53 | 3.48 | 7.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.54 Million | $ 4.03 Million | $ 3.26 Million |
Avecho Biotechnology Limited - Advanced Valuation Insights
This section examines the relationship between Avecho Biotechnology Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.70 |
| Latest Market Cap to Assets Ratio | 0.62 |
| Asset Growth Rate (YoY) | -31.7% |
| Total Assets | $5.00 Million |
| Market Capitalization | $3.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values Avecho Biotechnology Limited's assets below their book value (0.62 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Avecho Biotechnology Limited's assets decreased by 31.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Avecho Biotechnology Limited (1993–2024)
The table below shows the annual total assets of Avecho Biotechnology Limited from 1993 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.00 Million | -31.73% |
| 2023-12-31 | $7.32 Million | +118.78% |
| 2022-12-31 | $3.35 Million | -36.23% |
| 2021-12-31 | $5.25 Million | +56.38% |
| 2020-12-31 | $3.35 Million | -36.89% |
| 2019-12-31 | $5.32 Million | +10.69% |
| 2018-12-31 | $4.80 Million | -41.72% |
| 2017-12-31 | $8.24 Million | -38.30% |
| 2016-12-31 | $13.35 Million | -56.56% |
| 2015-12-31 | $30.74 Million | -39.60% |
| 2014-12-31 | $50.90 Million | +18.49% |
| 2013-12-31 | $42.96 Million | -33.00% |
| 2012-12-31 | $64.12 Million | -16.27% |
| 2011-12-31 | $76.58 Million | +42.42% |
| 2010-12-31 | $53.77 Million | -20.18% |
| 2009-12-31 | $67.36 Million | -2.64% |
| 2008-12-31 | $69.19 Million | -59.66% |
| 2007-12-31 | $171.52 Million | -1.14% |
| 2006-12-31 | $173.49 Million | +1.42% |
| 2005-12-31 | $171.07 Million | +50.02% |
| 2004-12-31 | $114.03 Million | +287.76% |
| 2003-12-31 | $29.41 Million | +98.19% |
| 2002-12-31 | $14.84 Million | -19.34% |
| 2001-12-31 | $18.40 Million | -11.81% |
| 2000-12-31 | $20.86 Million | +309.32% |
| 1999-12-31 | $5.10 Million | +214.49% |
| 1998-12-31 | $1.62 Million | -70.66% |
| 1997-12-31 | $5.52 Million | -83.27% |
| 1996-12-31 | $33.01 Million | -4.27% |
| 1995-12-31 | $34.48 Million | +208.07% |
| 1994-12-31 | $11.19 Million | -5.74% |
| 1993-12-31 | $11.88 Million | -- |